[ad_1]
Updated:
-
fromThomas Schmidtutz
to conclude
In the race for a corona vaccine, the Tübingen-based biotech company is enjoying major success. But patience is still needed until it is ready for the market.
- Researchers around the world are working on a vaccine against Crown*.
- The Tübingen biotech company has a first stumbling block taken.
- The Initial shot fall for the crucial Phase III tests.
Munich – The Tübingen biotechnology company Curevac sees himself developing a Crown*The vaccine is on its way. The first Phase I test results in humans were “very promising,” said one Curevac-Speaker Monday in front of Merkur.de *. The total of about 250 test subjects in four test centers in Tübingen, Hanover, Monk is Gent it would have shown “excellent tolerability at all doses tested from two to twelve micrograms”.
In addition, the people tested * showed “excellent formation of binding and neutralizing antibodies, as well as signs of activation of T cells”. The results were very similar to the immune response of patients who were infected with the Covid-19 virus, he said. Curevac-Chef, Franz-Werner Haas he said on Monday that “the interim dates for phase 1” are “very encouraging” and represent “a fundamental milestone in ours”. Covid19 vaccination program “.
In view of the positive results, the large-scale phase IIb / III will begin “this year,” said Curevac spokesman Thorsten Schüller. The vaccine will be tested on approximately 30,000 individuals in Europe and Latin America.
Curevac’s Corona vaccine: The company hopes to gain market approval by mid-2021
According to plans he wants Curevac then submit an application for so-called continued approval to the European Medicines Agency (EMA) in the first quarter of 2021. Hopefully, the vaccine could be available in mid-2021, he said.
In order to meet the anticipated demand, the company is working at full speed to expand its manufacturing capabilities. Building in Tübingen Curevac a new plant. It should start working in 2022 and, depending on the Amount of vaccine Make at least one billion cans a year. The building for it is already in place. Now they want to install the necessary systems, the spokesperson said.
For manufacturing facilities only Curevac Invest 75 million euros. In July, the biotech specialist obtained a loan from the European Investment Bank to finance it. In addition, existing plants are currently being “cloned several times”.
Corona vaccine from Curevac: innovative approach
Similar to the competitor Biontech from Mainz also has Curevac on the development of so-called messenger nucleic acids (mRNA) specialized. In this new approach, messengers would have to carry genetic blueprints for the production of unimaginably minuscule amounts of antigens in cells. The proteins produced should trigger a defense reaction of the immune system, which then also protects the body from viruses such as the coronavirus * SARS-CoV-2 should protect. Biontech is collaborating with US pharmaceutical giant Pfizer to develop a vaccine.
Curevac focuses on mRNA with a relatively low dose. The company expects this to be particularly well tolerated by the test subjects. Furthermore, a low dosage in subsequent production allows significant quantitative advantages per batch. * Merkur.de is part of the Ippen-Digital network
Source link
